Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte globulin (ATG), induces injury to blood vessels in the liver. According to ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...